The size of the Defibrillators market in the Asia Pacific is predicted to be worth USD 3.06 billion by 2026 from USD 2.13 billion in 2021, growing at a CAGR of 7.5% during the forecast period.
A defibrillator is a vital tool in cardiopulmonary resuscitation indicated in cardiac arrhythmia. As per the 2015 report issued by the Institute of Medicine, approximately 600,000 people are victims of cardiac arrest per year in the U.S., with about 65% of cases in out-of-hospital settings. The survival rate of the out-of-hospital environment is below 6%, whereas it is 24% in hospital settings. Inadequate operational knowledge among consumers regarding defibrillators and CPR results in a degenerate survival rate in out-of-hospital cardiac arrest cases.
The Asia-Pacific market is considered an emerging market due to CHD, stroke, and other heart conditions. It has grown moderately due to several factors, including rising healthcare costs, improving infrastructure and economics, and increasing living standards. Developing healthcare systems, large-scale CVD, the spread of stroke and heart disease, and private sector investment are expected to drive the market over the next few years.
The defibrillation procedure involves electrical shock to the heart to depolarize the myocardium and restore normal electrical impulses. The increasing focus of public and private sector defibrillators (PADs) on publicly available defibrillators (PADs) is driving the market growth. Besides, advanced defibrillator devices, a rapidly increasing aging population at high risk of target disease, and an increased incidence of heart disease across all age groups are driving the market growth.
Factors such as weak defibrillation policy reimbursement policies, under-equipped medical infrastructure, limited medical and patient awareness of various therapeutic devices, and high device costs challenge the market growth.
This research report on the APAC defibrillators market has been segmented and sub-segmented into the following categories:
By Product:
By End User:
By Country:
Regionally, it is capturing 20% of the global defibrillators market. The APAC Defibrillators market is one of the fastest-growing markets globally. The healthcare sector in the region is predicted to increase drastically, with huge advancements in the defibrillator industry in particular. The industry has grown significantly as a result of the adoption of innovative devices and technical advancements. In addition, due to lower surgery and treatment expenses, India, China, and Japan are medical tourism destinations for various countries. As a result, patients go great distances to receive high-quality care at low costs. In addition, medical tourism and an increase in heart patients in the region are driving up demand for implanted operations and devices.
The Chinese defibrillators market is anticipated to account dominant share in the APAC Defibrillators market during the forecast period. China has witnessed technological advancements in the healthcare sector, which provides lucrative growth opportunities for the market players in the country. In addition, increasing investments by the government, availability of advanced infrastructure, and growing geriatric population are propelling the market growth.
The Japanese defibrillators market is forecasted to be growing at a promising CAGR during the forecast period. In Japan, out of a total population of 126 million, about 27% of the population was over 65 years old. In 2023, the population is expected to drop to 123 million, with the geriatric population expected to rise. Compared to the younger population, the incidence of heat stroke in the elderly population is relatively high. According to the Institute for Health Metrics and Evaluation, ischemic heart disease affects roughly 0.2 million people in Japan. Ischemic heart disease affected 3.5 million people in the preceding decade, but this number has risen to 3.7 million, contributing to market growth.
The Australian defibrillators market is estimated to be one of the most lucrative regional markets in the Asia-Pacific region. According to the Australian Institute of Health and Welfare, 4,578 persons died in 2017 due to heart failure or cardiomyopathy. As a result, over the forecast period, the increased morbidity and mortality of cardiovascular illnesses and the efficacy of these devices in managing arrhythmias for a long time are likely to fuel the segment's growth.
KEY MARKET PLAYERS:
A few of the noteworthy companies operating in the APAC Defibrillators Market profiled in the report are Medtronic PLC (Ireland), St. Jude Medical, Inc. (U.S.), Boston Scientific Corporation (U.S.), BIOTRONIK SE & Co. KG (Germany), LivaNova PLC (U.K.), Koninklijke Philips N.V. (Netherlands), ZOLL Medical Corporation (U.S.), Cardiac Science Corporation (U.S.), Physio-Control, Inc. (U.S.), and Nihon Kohden Corporation (Japan).
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemiology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Product
5.1.1 Introduction
5.1.2 Implantable Cardioverter Defibrillators (ICDS)
5.1.2.1 Transvenous Implantable Cardioverter Defibrillators (T-ICDS)
5.1.2.1.1 Biventricular ICDS/Cardiac Resynchronization Therapy Defibrillators (CRT-DS)
5.1.2.1.2 Dual-Chamber ICDS
5.1.2.1.3 Single-Chamber ICDS
5.1.2.2 Subcutaneous Implantable Cardioverter Defibrillators (S-ICDS)
5.1.3 External Defibrillators
5.1.3.1 Automated External Defibrillators (AEDS)
5.1.3.1.1 Semi-Automated External Defibrillators
5.1.3.1.2 Fully Automated External Defibrillators
5.1.3.2 Manual External Defibrillators
5.1.3.3 Wearable Cardioverter Defibrillators (WCDS)
5.1.4 Y-o-Y Growth Analysis, By Product
5.1.5 Market Attractiveness Analysis, By Product
5.1.6 Market Share Analysis, By Product
5.2 End User
5.2.1 Introduction
5.2.2 Hospitals, Clinics, & Cardiac Centres
5.2.3 Pre-Hospitals
5.2.4 Public Access Markets
5.2.5 Home Care
5.2.6 Alternate Care Markets
5.2.7 Y-o-Y Growth Analysis, By End User
5.2.8 Market Attractiveness Analysis, By End User
5.2.9 Market Share Analysis, By End User
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Product
6.1.3.3 By End User
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Product
6.1.4.3 By End User
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Product
6.1.5.3 By End User
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Medtronic PLC
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 St. Jude Medical, Inc.
8.3 Boston Scientific Corporation
8.4 Philips Healthcare (A Division of Koninklijke Philips N.V.)
8.5 Zoll Medical Corporation (A Subsidiary of Asahi Kasei Corporation)
8.6 Biotronik Se & Co.Kg
8.7 Physio-Control International, Inc.
8.8 Cardiac Science Corporation (A Portfolio Company of Aurora Capital Group)
8.9 Sorin Group (Now Livanova PLC)
8.10 Nihon Kohden Corporation
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Apr 2021
